Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A Painful Decision for King and Acura

This article was originally published in RPM Report

Executive Summary

An FDA advisory committee rejects the idea of adding niacin to abusable drugs in order to provoke a flushing reaction and thereby discourage abuse. King and Acura respond by flushing the idea itself and focusing on physical barriers to abusability. For other sponsors, King's failed attempt to change FDA's mind looks like a study in what not to do.

You may also be interested in...



The Best Bad Deal of All Time? Pfizer/King and the Business Dynamics of Abuse Deterrence

Pfizer’s acquisition of King gave the company a chance to play in a new kind of market: abuse deterrent opioid pain relief formulations. Two years later, Pfizer is moving in the other direction, even as FDA’s actions validate the notion that there is an opportunity—and that the scale of Big Pharma can play a critical role.

King of Pain: Pfizer's Move into Abuse Resistant Opioids and the Virtues of Massive Scale

Pfizer’s $3.3 billion acquisition of King eliminates the primary opportunity for investors to play in the abuse-resistant formulation space and renewed questions about the logic of perpetual expansion atop Big Pharma. But the realities of the abuse resistant marketplace suggest it makes a good case for scale and diversity. Is this a sign of things to come in other drug classes?

King of Pain: Pfizer's Move into Abuse Resistant Opioids and the Virtues of Massive Scale

Pfizer’s $3.3 billion acquisition of King eliminates the primary opportunity for investors to play in the abuse-resistant formulation space and renewed questions about the logic of perpetual expansion atop Big Pharma. But the realities of the abuse resistant marketplace suggest it makes a good case for scale and diversity. Is this a sign of things to come in other drug classes?

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS080702

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel